Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I added 10,000 shares to my Oncosec stake last week around .51. I am now holding 43,000 shares long. In it to win it here. Data and trial approvals will win out over all the negativity in the market.
The new ATM is better terms than the Cantor ATM. If they do raise it will likely be at higher prices, then data into next year will move shares much higher. I firmly believe Oncosec gets PISCES approved next year. If they do get it take a look at where CPRX is hovering right now after nailing an FDA approval (not Oncology but still they will reap revenues). I would say Oncosec should at the very least be $5 on an approval. Merck buyout will happen at some point, or decent licensing deal. I am very long and still a believer here. Good luck fellow believers!
Oncosec will unveil their multi-gene construct tomorrow at AACR. This has been a long time coming. It could be the beginning of very disruptive tech. Pre-clinical and clinical data will be released as well as intended future target indications. Oncosec could be $1 tomorrow or by friday's symposium, whenever data and future prospects are revealed.
simply sit on this until labs open and revenues pour in.
The partnership that HEMP INC. and Digipath Inc. have is a smart move to capitalize on the Hemp legalization while we wait for federal laws to change for THC.
Digipath Labs will be opening at HEMP production facilities starting in Oregon. I see both these undervalued companies rising on the back of Hemp legalization. The market is just waking up to both companies.
Digipath expansion plans include ; "independently to California, in Humboldt County" ....so looks like California is also coming soon as well as Colombia and 3 HEMP Inc. labs....Orgeon, North Carolina, and Arizona. https://digipath.com/current-projects/
Digipath Inc. CEO Todd Denkin's Upcoming Visit to Hemp University to Talk about Hemp Lab Testing
Definitely real potential with Digipath. The partnering with HEMP to open more labs was a smart move. Opening a lab in Colombia is an equally smart move.
It will happen soon. Digipath has made some good headlines recently. This is a good place to be in. Simply need patience and the market will come around to it. Digipath will definitely be seeing higher revenue in the near future.
Digipath Inc. has the opportunity of a lifetime right now. Shareholders would be wise to stick around for the ride.If I think as new labs become opperational, Digipath should take a stab at an uplisting to a major exchange. Cannabis/hemp testing labs are absolutely ignored right now.
Digipath, Inc. (DIGP) supports the cannabis and hemp industry’s best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis and hemp industry to ensure producers, consumers, and patients know exactly what is in the cannabis and hemp they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization. Digipath, Inc. and Hemp, Inc. has entered into an agreement for Digipath to install a state of the art testing lab in all of Hemp, Inc.’s locations starting with the Medford, Oregon Local Processing Center. CEO Todd Denkin is also scheduled to speak at the upcoming Hemp University seminar.
The CEO mentioned it in todays pr. The link is in my previous post.
Their first lab with HEMP INC. will open in Oregon soon.
Digipath's Orser and Denkin to Present at Hemp University https://www.marketwatch.com/press-release/digipaths-orser-and-denkin-to-present-at-hemp-university-2019-03-21
California and Colombia are key to Digipath growth strategy. Nice to see that their new subsidiary is located in Colorado....a huge market for cannabis (GroSciences Inc | 1434 Spruce Street Suite 100 Boulder, CO 80302)
Somebody really trying to shake the tree today. Digipath CEO seems very confident that expansion plans are full steam ahead in 2019. It is a huge opportunity here.....if they can execute the plans. I think they can.
If this agreement is still happening it looks non-dilutive to me.
An acquisition or Joint Venture would be a smart move for Digipath in the California market rather than starting from scratch. California is a huge market.
In the interest of growth Digipath would make out fine if they need to raise capital to fund their expansion plans. Long-Term gains in the cannabis industry comes at short-term pain with capital raises. All about growth. DIGP can earn revenues of $9to $18 million per lab. Growth is coming for this underappreciated company. Buy any pullbacks.
Digipath wants to acquire or JV lab in California and open a lab in Colombia. They said they will expand through revenues but this proxy filing means they want to have the ability to raise capital....not diluting yet.
Important words from Digipath CEO regarding potential revenue estimates; Cost to open a high-end testing lab= $2-2.5 mil. Potential revenue per lab per year = $9.5 to $18 mil. Best market would be California and Colorado for revenues. 6 total labs would bring in alot of revenues for Digipath Labs.
Digipath Featured in CannaInvestor Magazine https://www.prnewswire.com/news-releases/digipath-featured-in-cannainvestor-magazine-300814524.html
CEO Todd Denkin of Digipath Inc DIGP Discusses New Terpene Pesticide Technology with MoneyTV
Digipath Labs has been mentioned in multiple articles lately alongside heavyweight companies like Perkin Elmer, Inc., and GE Healthcare as industry key players. Digipath was recently named a top ten testing lab also.....and much to the surprise of their own CEO, Todd Denkin.....he said the recognition was much appreciated.
Lab Workflow Solutions Market- Key Companies http://www.digitaljournal.com/pr/4209161
Quality over quantity. One reputable lab (Digipath) is worth 8 shady labs (EVIO). Digipath recently named a top 10 testing lab....not surprised ...and they are expanding their model testing lab to at least 6 total labs in the next year. The Nevada site will be a training lab for their expansion.....accotding to Digipath CEO.
I would definitely hold this long term. Digipath is going to open 3 labs with HEMP, 1 lab in California and 1 lab in Colombia.....from 1 lab to 6 labs likely by end of this year. Huge growth potential here.
For people predicting that Oncosec would trade at book value, we got pretty close to it today. Rediculous in my opinion. At AACR Oncosec will disclose not only pre-clinical data for the multi-gene construct but also the target indication for this new product which could be market disruptive. Not surprised at all that the stock is under pressure right now while we wait for more details. I believe this is the buying opportunity of a lifetime.
looking at the recent trades, alot of buyers just came in on this drop.
Volume is pretty low so seems like price is being depressed to me. Market fears dilution right now. It sucks but Oncosec probably should have raised before SITC when price was touching $2. Oncosec has an ATM with Cantor but recently stated they have not used it and are at no obligation to do so. I suppose they could hold out for another 6 months before needing to tap the ATM. What investors need is a boost of faith such as a licensing deal for the new product candidate. It could be truly market disruptive....and maybe Big Pharma would jump in before trials begin. With another waiting period before either TNBC or PISCES updates Oncosec shares have been under pressure. Would be nice to get some more exciting announcements before AACR next month. A licensing deal for the multi-gene construct before trials get underway is not out of the question given that it looks extremely promising. A recent example of a huge licensing deal is the JNJ licensing deal with Locus Bio (private company) for more than $800 million and $20 million upfront. That is the kind of deal Oncosec needs right now with this new tech they are unveiling.
Maybe somebody lost faith and unloaded all their shares. They might be very sorry monday morning if we get pipeline news.
We need news monday so we can leave behind these lower prices. GLTU as well.
Let's hope for news monday morning Jeff. I know people don't have any faith in anything related to Alpha Holdings....but they did mention March 3rd as the day Lung Cancer would be announced as an expansion of Oncosec's pipeline.People saying info may be wrong in the Korean translation....but I see the information on their site as clear enough to be hopefull of this. They say on their website that they expect Oncosec shares to be rerated with the expansion of their pipeline regarding the new product candidate.
Oncosec shares are being pushed down intentionally on low volume today. We may get a pipeline announcement monday morning regarding the new multi-gene construct which will be presented at AACR next month. Market Makers at work today...ignore.
Exactly, Howard. Oncosec may just be in position to leapfrog over Big Pharma (Merck, Bristol Myers, Roche)....if they can bypass the need for a checkpoint (KEYTRUDA, OPDIVO, or TECENTRIQ). If Merck were smart they would at the very least sign an exclusive licensing deal with Oncosec if they are not going to buyout the company. This is getting more interesting.....and lets see how Alpha Holdings figures into the mix....they are the largest Oncosec shareholders at this point.
Buy orders coming in.
Being pushed down today. I am holding strong.
Yup! Buying opportunity here.
All I know is that DIGP did not gaup up from .09 to .33 for no reason. Eyes are on it and lab expansion....means more revenues and higher share price. 2019 will be a good year for them.